Home > News > Analysis: Sanofi's Taxotere keeps top spot
March 27th, 2007
Analysis: Sanofi's Taxotere keeps top spot
Abstract:
A nanoparticle formulation of Abraxis/AstraZeneca's Abraxane may also help drive market growth. A phase 2 trial comparing Abraxane to Taxotere in the metastatic breast cancer setting is slated to begin this year. If Abraxane has a strong showing in this trial, it could help propel growth of the market even more, the report forecasts.
Source:
upi.com
Bookmark:
Nanomedicine
How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013
MU Researchers Develop Radioactive Nanoparticles that Target Cancer Cells: This is an early step toward developing therapies for metastasized cancers, MU scientist says May 21st, 2013
Nanoparticle Delivers Large Protein Complex to Cancer Cell Nucleus May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals
International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013
Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013
Nanoparticle Harnesses Powerful Radiation Therapy for Cancer May 20th, 2013
Microneedle-Delivered Nanoparticles Boost Antitumor Vaccines May 20th, 2013
Human Interest/Art
Oh, Christmas tree, oh Christmas tree: A nano end for Christmas tree needles January 2nd, 2013
INIC Inks MoU to Apply Nanotechnology in Iran's Carpet Industry December 18th, 2012
IBN Welcomes Its First 9-Year-Old ‘Scientist’: IBN and Make-A-Wish Foundation Singapore Make Kidney Patient’s Dream Come True December 10th, 2012
The music of the silks: Researchers synthesize a new kind of silk fiber — and find that music can help fine-tune the material’s properties November 28th, 2012